Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Aegirbio AB ("Aegirbio") has received an Intention to Grant notice from the European Patent Office ("EPO") for its patent application for the quantitative, point-of-care and point-of-need, thyroid hormones test product (Thyrolytics). In essence, this means that the EPO intends to approve the company's application.
The patent application, with application number PCT/EP2019/068869, for which the EPO has issued an Intention to Grant notice, refers to the Thyrolytics' biosensor product for use in detecting and quantifying the thyroid hormones T3 and T4 using a capillary blood sample. The patent protects the use of two key enzymes, DIO II and DIO III, for diagnostic applications. The notice of the Intention to Grant means that the EPO intends to approve the company's patent application but that a number of administrative steps remain before a final notice of approval can be issued. The patent, when granted, provides protection of the device in Europe until 2039.
In addition to Europe, Aegirbio has submitted patent applications for Thyrolytics's device in several other territories, including the United States, Japan India and China.
"The granting of a patent for our Thyrolytics device is an important part of our efforts to build value in our diagnostic patent portfolio. In addition to the device, Thyrolytics is developing an ambitious candidate drug aimed to aid 20% of hypothyroidism patients that do not respond to Levothyroxine today" says Mohamad Takwa, CEO of Thyrolytics.
"We are very pleased that the examination of our application was completed quickly and that we have now taken a big step towards obtaining a patent in a large and important market such the thyroidism market. In Sweden we have half a million thyroidism patients according to the Swedish thyroid association. With this we take an additional step towards becoming world leader in Therapeutic Drug Monitoring" says Martin Linde, CEO of Aegirbio.